أعرض في EDS

Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial

التفاصيل البيبلوغرافية
العنوان: Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
المؤلفون: Joyce F. Liu, Alison Hannah, Virginia Paton, Susan K. Lyman, Olga Vasiljeva, Ivan A. Zein, Tam Dang, Song Wang, C. Willemien Menke van der Houven van Oordt, Guus A.M.S. van Dongen, Gerben J.C. Zwezerijnen, Marc C. Huisman, Danielle J. Vugts, Iris H.C. Miedema, Stella K. Kim, James J. Harding, Shadia Jalal, Javier Garcia-Corbacho, Misako Nagasaka, Patricia LoRusso, Randy F. Sweis, Rachel E. Sanborn, Nataliya Uboha, Funda Meric-Bernstam, Alexander Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Valentina Boni
بيانات النشر: American Association for Cancer Research (AACR), 2023.
سنة النشر: 2023
الوصف: Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20af64024eca128b7e651ebd8e6392cb
https://doi.org/10.1158/1078-0432.22486622
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....20af64024eca128b7e651ebd8e6392cb
قاعدة البيانات: OpenAIRE
الوصف
الوصف غير متاح.